GlassScriptPhysician profile
Azimuddin Kazi
NPI 1750321428
$16,117.93
in general payments reported to CMS, 2019-2025
52 companies · $2,545 in 2025
The $2,545 reported for 2025 was more than what 81% of Neurology With Special Qualifications In Child Neurology providers received nationally (typical 2025 total: $275).
See the full distribution for Neurology with Special Qualifications in Child Neurology
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,710 · 2020: $901 · 2021: $4,171 · 2022: $1,897 · 2023: $2,579 · 2024: $2,315 · 2025: $2,545.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,438.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,438.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $3,558.41 | 2019-2025 | Qelbree, Qelbree |
| Ucb, INC. | $2,081.37 | 2019-2025 | Briviact, Nayzilam, Rystiggo |
| Tris Pharma INC | $1,412.77 | 2019-2025 | Dyanavel Xr, Onyda Xr, Quillichew Er |
| Sk Life Science, INC. | $912.68 | 2020-2025 | Xcopri |
| Corium, LLC | $890.86 | 2022-2025 | Azstarys |
| Argenx US, INC. | $699.57 | 2022-2025 | Vyvgart Hytrulo, Vyvgart |
| Biogen, INC. | $669.15 | 2019-2025 | Vumerity, Tysabri, Skyclarys |
| Eisai INC. | $647.45 | 2019-2025 | |
| Abbvie INC. | $640.13 | 2022-2025 | |
| Acadia Pharmaceuticals INC | $408.39 | 2019-2025 | Nuplazid |
| Lundbeck LLC | $389.87 | 2019-2025 | Vyepti |
| Teva Pharmaceuticals USA, INC. | $383.62 | 2019-2025 | Ajovy, Austedo Xr, Austedo Xr |
| Emd Serono, INC. | $335.41 | 2019-2025 | Mavenclad |
| Amneal Pharmaceuticals LLC | $284.10 | 2019-2025 | Crexont, Rytary, Lyvispah |
| Alexion Pharmaceuticals, INC. | $240.87 | 2019-2025 | Ultomiris |
Show all 52 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Azimuddin Kazi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.